Repurposed asthma drug reverses diabetes in mouse study

02/11/2013 | Genetic Engineering & Biotechnology News

Amlexanox, an off-patent asthma drug, reversed obesity, diabetes and fatty liver disease in mice, according to a study published in Nature Medicine. The drug appears to inhibit the IKK(epsilon) and TBK1 genes, which might allow the metabolic system to burn more energy, University of Michigan Life Sciences Institute researcher Alan Saltiel said. Researchers plan to test the drug in clinical trials and are working on optimized formulas.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Executive Officer
UCare Minnesota
Minneapolis, MN